Vinva Investment Management Ltd Buys 385 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Vinva Investment Management Ltd increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 12.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,469 shares of the company’s stock after buying an additional 385 shares during the quarter. Vinva Investment Management Ltd’s holdings in IDEXX Laboratories were worth $1,775,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Chicago Partners Investment Group LLC lifted its position in shares of IDEXX Laboratories by 16.7% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company’s stock worth $340,000 after buying an additional 96 shares during the period. Manning & Napier Advisors LLC acquired a new stake in IDEXX Laboratories during the 2nd quarter valued at $20,418,000. Oppenheimer Asset Management Inc. increased its holdings in IDEXX Laboratories by 13.8% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company’s stock valued at $5,825,000 after purchasing an additional 1,453 shares in the last quarter. National Pension Service increased its holdings in IDEXX Laboratories by 7.3% during the 3rd quarter. National Pension Service now owns 185,972 shares of the company’s stock valued at $93,957,000 after purchasing an additional 12,647 shares in the last quarter. Finally, EFG Asset Management Americas Corp. increased its holdings in IDEXX Laboratories by 45.3% during the 2nd quarter. EFG Asset Management Americas Corp. now owns 12,728 shares of the company’s stock valued at $6,201,000 after purchasing an additional 3,966 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.0 %

Shares of IDEXX Laboratories stock opened at $421.75 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The business has a fifty day simple moving average of $451.91 and a 200 day simple moving average of $478.11. The stock has a market cap of $34.53 billion, a PE ratio of 40.67, a price-to-earnings-growth ratio of 3.68 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million during the quarter, compared to analysts’ expectations of $980.32 million. During the same period in the previous year, the firm earned $2.53 earnings per share. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. Research analysts predict that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on IDXX. Stifel Nicolaus dropped their price target on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. JPMorgan Chase & Co. dropped their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Barclays dropped their price target on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Piper Sandler reaffirmed a “neutral” rating and set a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Finally, StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $552.38.

Insider Buying and Selling

In related news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares of the company’s stock, valued at $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.11% of the stock is owned by insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.